CCB
HRTX icon

Cutter & Co Brokerage’s Heron Therapeutics HRTX Stock Holding History

Cutter & Co Brokerage’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,465
Closed -$80.2K – 76
2025
Q1 		$80.2K Buy
36,465
+3,330
+10% +$6.46K 0.02% 175
2024
Q4 		$50.7K Buy
33,135
+13,600
+70% +$22K 0.01% 201
2024
Q3 		$38.9K Buy
+19,535
New +$46.6K 0.01% 208
2023
Q3 		– Sell
-10,180
Closed -$11.8K – 217
2023
Q2 		$11.8K Sell
10,180
-1,385
-12% -$2.47K ﹤0.01% 211
2023
Q1 		$17.5K Sell
11,565
-1,090
-9% -$2.73K 0.01% 214
2022
Q4 		$31.6K Sell
12,655
-250
-2% -$805 0.01% 207
2022
Q3 		$54K Sell
12,905
-200
-2% -$783 0.02% 213
2022
Q2 		$37K Sell
13,105
-275
-2% -$1.1K 0.01% 222
2022
Q1 		$77K Sell
13,380
-2,945
-18% -$21.6K 0.02% 221
2021
Q4 		$149K Sell
16,325
-14,510
-47% -$148K 0.04% 256
2021
Q3 		$330K Buy
30,835
+2,370
+8% +$28.9K 0.08% 199
2021
Q2 		$442K Buy
28,465
+625
+2% +$9.94K 0.1% 166
2021
Q1 		$451K Sell
27,840
-5,500
-16% -$98K 0.11% 161
2020
Q4 		$706K Buy
33,340
+2,860
+9% +$49.7K 0.19% 117
2020
Q3 		$452K Buy
30,480
+275
+0.9% +$4.29K 0.13% 136
2020
Q2 		$444K Buy
30,205
+480
+2% +$7.89K 0.14% 125
2020
Q1 		$349K Buy
29,725
+1,040
+4% +$19.6K 0.13% 136
2019
Q4 		$674K Buy
28,685
+6,175
+27% +$137K 0.24% 94
2019
Q3 		$416K Buy
22,510
+1,440
+7% +$26.5K 0.13% 166
2019
Q2 		$392K Buy
21,070
+6,415
+44% +$128K 0.12% 179
2019
Q1 		$358K Buy
14,655
+3,270
+29% +$85.6K 0.1% 179
2018
Q4 		$295K Hold
11,385
– – 0.11% 180
2018
Q3 		$360K Hold
11,385
– – 0.12% 161
2018
Q2 		$442K Buy
11,385
+765
+7% +$24.4K 0.17% 128
2018
Q1 		$293K Buy
+10,620
New +$241K 0.12% 173

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cutter & Co Brokerage's HRTX Position: Q2 2025 in Review

Cutter & Co Brokerage sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 36,465 shares — an estimated $80.2K sold.

Cutter & Co Brokerage first reported a position in HRTX in Q1 2018 and held it in 25 quarters. The position peaked at $706K in Q4 2020. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Cutter & Co Brokerage reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cutter & Co Brokerage sold 36,465 Heron Therapeutics shares in Q2 2025, an estimated $80.2K.
  • Cutter & Co Brokerage first reported a position in Heron Therapeutics in Q1 2018 and held it in 25 quarters.
  • Cutter & Co Brokerage's Heron Therapeutics position peaked at $706K in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Cutter & Co Brokerage's 13F filing for Q2 2025.